Cargando…
Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients—Real-World Data From Hungary
Pomalidomide is a third generation immunomodulatory drug in the treatment of refractory and relapsed multiple myeloma patients. Our aim was to investigate the efficacy and safety of pomalidomide therapy in a real world setting. Eighty-six Hungarian patients were included, 45 of whom received pomalid...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9573944/ https://www.ncbi.nlm.nih.gov/pubmed/36262875 http://dx.doi.org/10.3389/pore.2022.1610645 |
_version_ | 1784810989932249088 |
---|---|
author | Lovas, Szilvia Obajed Al-Ali, Nóra Varga, Gergely Szita, Virág Alizadeh, Hussain Plander, Márk Rajnics, Péter Illés, Árpád Szemlaky, Zsuzsa Mikala, Gábor Váróczy, László |
author_facet | Lovas, Szilvia Obajed Al-Ali, Nóra Varga, Gergely Szita, Virág Alizadeh, Hussain Plander, Márk Rajnics, Péter Illés, Árpád Szemlaky, Zsuzsa Mikala, Gábor Váróczy, László |
author_sort | Lovas, Szilvia |
collection | PubMed |
description | Pomalidomide is a third generation immunomodulatory drug in the treatment of refractory and relapsed multiple myeloma patients. Our aim was to investigate the efficacy and safety of pomalidomide therapy in a real world setting. Eighty-six Hungarian patients were included, 45 of whom received pomalidomide ± an alkylating agent, while in 38 of them pomalidomide was combined with a proteasome inhibitor. 56 patients (65%) showed any response to the treatment with 18 complete or very good partial remissions and 38 partial remissions. At a median duration of follow-up of 18.6 months, the median progression-free survival (PFS) was 9.03 months, while the median overall survival (OS) was 16.53 months in the whole cohort. Patients with early stage disease (R-ISS 1 and 2) had better survival results than those with stage 3 myeloma (p = 0.002). Neither the number of prior treatment lines, nor lenalidomide refractoriness had a significant impact on PFS. PFS was found similar between the cohort of patients with impaired renal function and the cohort without kidney involvement. During the study, eight mortal infections and two fatal bleeding complications occurred, however, mild hematologic and gastrointestinal toxicities were identified as the most frequent adverse events. The results of our investigations confirm that pomalidomide is an effective treatment option for relapsed/refractory MM, besides, the safety profile is satisfactory in subjects with both normal and impaired renal function. |
format | Online Article Text |
id | pubmed-9573944 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95739442022-10-18 Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients—Real-World Data From Hungary Lovas, Szilvia Obajed Al-Ali, Nóra Varga, Gergely Szita, Virág Alizadeh, Hussain Plander, Márk Rajnics, Péter Illés, Árpád Szemlaky, Zsuzsa Mikala, Gábor Váróczy, László Pathol Oncol Res Pathology and Oncology Archive Pomalidomide is a third generation immunomodulatory drug in the treatment of refractory and relapsed multiple myeloma patients. Our aim was to investigate the efficacy and safety of pomalidomide therapy in a real world setting. Eighty-six Hungarian patients were included, 45 of whom received pomalidomide ± an alkylating agent, while in 38 of them pomalidomide was combined with a proteasome inhibitor. 56 patients (65%) showed any response to the treatment with 18 complete or very good partial remissions and 38 partial remissions. At a median duration of follow-up of 18.6 months, the median progression-free survival (PFS) was 9.03 months, while the median overall survival (OS) was 16.53 months in the whole cohort. Patients with early stage disease (R-ISS 1 and 2) had better survival results than those with stage 3 myeloma (p = 0.002). Neither the number of prior treatment lines, nor lenalidomide refractoriness had a significant impact on PFS. PFS was found similar between the cohort of patients with impaired renal function and the cohort without kidney involvement. During the study, eight mortal infections and two fatal bleeding complications occurred, however, mild hematologic and gastrointestinal toxicities were identified as the most frequent adverse events. The results of our investigations confirm that pomalidomide is an effective treatment option for relapsed/refractory MM, besides, the safety profile is satisfactory in subjects with both normal and impaired renal function. Frontiers Media S.A. 2022-10-03 /pmc/articles/PMC9573944/ /pubmed/36262875 http://dx.doi.org/10.3389/pore.2022.1610645 Text en Copyright © 2022 Lovas, Obajed Al-Ali, Varga, Szita, Alizadeh, Plander, Rajnics, Illés, Szemlaky, Mikala and Váróczy. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pathology and Oncology Archive Lovas, Szilvia Obajed Al-Ali, Nóra Varga, Gergely Szita, Virág Alizadeh, Hussain Plander, Márk Rajnics, Péter Illés, Árpád Szemlaky, Zsuzsa Mikala, Gábor Váróczy, László Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients—Real-World Data From Hungary |
title | Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients—Real-World Data From Hungary |
title_full | Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients—Real-World Data From Hungary |
title_fullStr | Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients—Real-World Data From Hungary |
title_full_unstemmed | Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients—Real-World Data From Hungary |
title_short | Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients—Real-World Data From Hungary |
title_sort | pomalidomide treatment in relapsed/refractory multiple myeloma patients—real-world data from hungary |
topic | Pathology and Oncology Archive |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9573944/ https://www.ncbi.nlm.nih.gov/pubmed/36262875 http://dx.doi.org/10.3389/pore.2022.1610645 |
work_keys_str_mv | AT lovasszilvia pomalidomidetreatmentinrelapsedrefractorymultiplemyelomapatientsrealworlddatafromhungary AT obajedalalinora pomalidomidetreatmentinrelapsedrefractorymultiplemyelomapatientsrealworlddatafromhungary AT vargagergely pomalidomidetreatmentinrelapsedrefractorymultiplemyelomapatientsrealworlddatafromhungary AT szitavirag pomalidomidetreatmentinrelapsedrefractorymultiplemyelomapatientsrealworlddatafromhungary AT alizadehhussain pomalidomidetreatmentinrelapsedrefractorymultiplemyelomapatientsrealworlddatafromhungary AT plandermark pomalidomidetreatmentinrelapsedrefractorymultiplemyelomapatientsrealworlddatafromhungary AT rajnicspeter pomalidomidetreatmentinrelapsedrefractorymultiplemyelomapatientsrealworlddatafromhungary AT illesarpad pomalidomidetreatmentinrelapsedrefractorymultiplemyelomapatientsrealworlddatafromhungary AT szemlakyzsuzsa pomalidomidetreatmentinrelapsedrefractorymultiplemyelomapatientsrealworlddatafromhungary AT mikalagabor pomalidomidetreatmentinrelapsedrefractorymultiplemyelomapatientsrealworlddatafromhungary AT varoczylaszlo pomalidomidetreatmentinrelapsedrefractorymultiplemyelomapatientsrealworlddatafromhungary |